$MBNKO

MEDALLION FINANCIAL CORP (MBNKO): Regulation FD Disclosure

MEDALLION FINANCIAL CORP (MBNKO) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 FOR IMMEDIATE RELEASE: MEDALLION BANK ANNOUNCES LAUNCH OF SERIES G PREFERRED STOCK OFFERING SALT LAKE CITY, UT – September 22, 2026 – Medallion Bank (Nasdaq: MBNKO), an FDIC-insured bank providing consumer loans for the purchase of recreational vehicles, boats, and h

Original reporting
Published Sep 22, 2026, 8:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$MBNKO
Neutral
medium confidence
Mentioned
$MBNKO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MBNKONeutralMed
01

Why it matters

The new preferred issuance may dilute existing equity holders and affect the stock's liquidity, while proceeds could be used to redeem older preferred securities.

02

Market read

Primary disclosure of a capital raise for a small‑cap bank; relevant for traders monitoring dilution risk.

03

What to watch

Potential redemption of Series E preferred could free up capital, altering the net impact.

Relevance 6/10Novelty 7/10Timing: filed Sep 22 2026

Background

Medallion Bank, a subsidiary of Medallion Financial Corp., provides consumer loans for RVs, boats, and home improvements and is issuing additional Series G preferred shares.

Company-level read

Ticker impact

$MBNKONeutralMedium confidence
Context

Medallion Bank filed an 8‑K announcing a reopening of its Series G preferred stock offering, a fresh capital raise for the subsidiary.

Expected impact

Short‑term downward pressure on equity price; longer‑term support if proceeds improve balance sheet.

Evidence & confidence

The offering size is not disclosed, but any new preferred issuance can affect share supply and investor perception.

Market effects

May signal increased financing activity in the niche consumer‑loan banking sector.

Limited to U.S. regional banking market; no broader macro effect.

Low

Counterpoint

If the preferred offering is oversubscribed, the equity could rally on perceived confidence.

Key entities

  • Medallion Bank

    Issuer of the Series G preferred stock offering.

  • Piper Sandler & Co.

    Joint book‑running manager for the offering.

Related articles

$RKTOHighAI 8/10

Rocket One Inc. (RKTO): Other Events

Rocket One Inc. (RKTO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Rocket One Signs Definitive Agreement to Acquire Revenue-Generating Tracer Drone Technologies, Accelerating AI and Counter-UAS Expansion Across Public Safety and Defense Markets Transaction would add an operating drone sales, services and training platform serving pu

$INNVMedAI 8/10

Why is InnovAge stock sliding today?

InnovAge's stock fell 9.5% in after-hours trading after affiliated investment funds of Apax Partners and Welsh, Carson, Anderson & Stowe announced a secondary offering of 10 million shares. The company will not receive proceeds, signaling insider distribution. The broader market's performance did not mitigate the decline. InnovAge's Q4 revenue exceeded estimates, but earnings per share fell short. Barclays, Goldman Sachs, and Wells Fargo are managing the deal.

$IPARMed

INTERPARFUMS INC (IPAR): Other Events

INTERPARFUMS INC (IPAR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 FOR IMMEDIATE RELEASE INTERPARFUMS, INC. ANNOUNCES EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH PUMA New York, New York, September 22, 2026, Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today announced that it has entered into an exclusive, wo

$VTGNMedAI 8/10

Vistagen Therapeutics, Inc. (VTGN): Other Events

Vistagen Therapeutics, Inc. (VTGN) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Fasedienol nasal spray was well-tolerated in patients with social anxiety disorder with no new

$LONAMed

LeonaBio, Inc. (LONA): Other Events

LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. In December 2025, as part of a private placement, LeonaBio, Inc. (the “Company”) issued warrants to purchase an aggregate of 23,031,494 shares of its common stock (the “Series A Common Warrants”). The Series A Common Warrants have an exercise price of $6.3